Samuel M. Liang assumed the role of President and Chief Executive Officer of MEDRAD, INC. in July of 2010. Before joining MEDRAD, Liang served as President and CEO of Vascular Therapies, LLC, a start-up company developing a combination drug-device product for surgery.
Prior to that, he spent 24 years at Cordis, a Johnson & Johnson company, in various engineering, international, strategic and commercial leadership roles including: vice president of marketing for Cordis Cardiology, worldwide vice president of Commercial Operations for Cordis Endovascular and Disease State Leader/GM of Cordis Neurovascular.
Liang was also the vice president of the Cordis Global Stent franchise and worldwide vice president for Cypher programs where he led all aspects of the company’s stent franchise and its initiatives in drug-eluting stents. This included commercializing and launching Cypher, the world’s first drug-eluting stent along with unprecedented incremental reimbursement at launch in the U.S.
Liang holds a B.S.E. in Mechanical Engineering and Material Sciences from Duke University and a Masters in Management from the Kellog Graduate School of Management, Northwestern University.